PharmaCyte Biotech (NASDAQ:PMCB – Get Free Report) and Coeptis Therapeutics (NASDAQ:COEP – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.
Risk & Volatility
PharmaCyte Biotech has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.9, suggesting that its stock price is 190% less volatile than the S&P 500.
Institutional & Insider Ownership
34.2% of PharmaCyte Biotech shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 7.3% of PharmaCyte Biotech shares are owned by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PharmaCyte Biotech | N/A | N/A | $330,000.00 | $0.53 | 3.15 |
| Coeptis Therapeutics | $80,000.00 | 108.45 | -$21.27 million | ($0.29) | -0.73 |
PharmaCyte Biotech has higher earnings, but lower revenue than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than PharmaCyte Biotech, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings for PharmaCyte Biotech and Coeptis Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PharmaCyte Biotech | 0 | 0 | 0 | 0 | 0.00 |
| Coeptis Therapeutics | 0 | 1 | 0 | 0 | 2.00 |
Profitability
This table compares PharmaCyte Biotech and Coeptis Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PharmaCyte Biotech | N/A | 1.38% | 0.71% |
| Coeptis Therapeutics | N/A | -1,094.50% | -219.97% |
Summary
PharmaCyte Biotech beats Coeptis Therapeutics on 7 of the 10 factors compared between the two stocks.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
About Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
